Sarclisa Isatuximab Injection

1. Indications and Usage
Status: Investigational Drug (Not currently FDA approved).
Target Populations (Clinical Trials):
Non-Hodgkin Lymphoma (NHL): Previously untreated or relapsed/refractory CD22-positive B-cell non-Hodgkin lymphoma.
Systemic Lupus Erythematosus (SLE): Patients with moderate-to-severe active SLE (Development discontinued/modified due to lack of efficacy in Phase III).
Acute Lymphoblastic Leukemia (ALL): Pediatric patients with CD22-positive ALL.
2. Dosage and Administration
Route of Administration:
For Intravenous (IV) Infusion ONLY. Do not administer as an IV push or bolus.
Recommended Dosage (Based on Historical Trials):
Monotherapy (NHL): 360 mg/m² IV over 1 hour on Days 1, 8, 15, and 22 of a 28-day cycle.
Combination Therapy: Investigated in combination with chemotherapy (e.g., CHOP) or other monoclonal antibodies (e.g., Rituximab).
Premedication:
In clinical trials, premedication with acetaminophen and diphenhydramine was often administered prior to infusion to mitigate infusion-related reactions.
3. Mechanism of Action
CD22 Antigen Binding:
Epratuzumab is a humanized IgG1κ monoclonal antibody that binds to an extracellular loop of the CD22 antigen (a sialic acid-binding Ig-like lectin) expressed on B-lymphocytes.
Immunomodulation:
Unlike anti-CD20 antibodies (e.g., Rituximab), Epratuzumab induces minimal complement-dependent cytotoxicity (CDC).
It primarily modulates B-cell signaling pathways and induces B-cell internalization (endocytosis) of the CD22 receptor, thereby regulating B-cell activation and proliferation.
4. Safety and Warnings
Infusion-Related Reactions (IRR):
Common side effects include fever, chills, rigors, hypotension, and nausea. Most are mild to moderate (Grade 1-2).
Immunosuppression:
Potential risk of transient B-cell depletion and increased susceptibility to infections.
Hepatic Toxicity:
Transient elevations in serum transaminases (ALT/AST) have been observed in clinical trials.
5. Adverse Reactions
Most Common:
Infusion-related reactions (fever, chills), nausea, headache, fatigue, and upper respiratory tract infections.
Laboratory Abnormalities:
Transient thrombocytopenia, leukopenia, and elevated liver enzymes.
6. Drug Interactions
Live Vaccines:
Contraindicated during and after treatment until immune reconstitution.
Chemotherapy:
No pharmacokinetic interactions were observed when combined with chemotherapy agents in trials, but additive immunosuppressive effects are possible.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Epratuzumab.
Appearance: Clear, colorless to slightly yellow liquid.
Storage: Store at 2°C–8°C. Do not freeze or shake.